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Sagopilone, a fully synthetic epothilone, is amicrotubule-stabilizing agent optimized for high
in vitro and in vivo activity against a broad range of tumor models, including those resistant
to paclitaxel and other systemic treatments. Sagopilone development is accompanied by
translational research studies to evaluate the molecular mode of action, to recognize mech-
anisms leading to resistance, to identify predictive response biomarkers, and to establish
a rationale for combination with different therapies. Here, we proﬁled sagopilone activity
in breast cancer cell lines. To analyze the mechanisms of mitotic arrest and apoptosis and
to identify additional targets and biomarkers, an siRNA-based RNAi drug modiﬁer screen
interrogating 300 genes was performed in four cancer cell lines. Defects of the spindle
assembly checkpoint (SAC) were identiﬁed to cause resistance against sagopilone-induced
mitotic arrest and apoptosis. Potential biomarkers for resistance could therefore be func-
tional defects like polymorphisms or mutations in the SAC, particularly in the central SAC
kinase BUB1B. Moreover, chromosomal heterogeneity and polyploidy are also potential
biomarkers of sagopilone resistance since they imply an increased tolerance for aberrant
mitosis. RNAi screening further demonstrated that the sagopilone-induced mitotic arrest
can be enhanced by concomitant inhibition of mitotic kinesins, thus suggesting a potential
combination therapy of sagopilone with a KIF2C (MCAK) kinesin inhibitor. However, the
combination of sagopilone and inhibition of the prophase kinesin KIF11 (EG5) is antagonis-
tic, indicating that the kinesin inhibitor has to be highly speciﬁc to bring about the required
therapeutic beneﬁt.
Keywords: translational cancer research, breast cancer,microtubule-stabilizing agent, epothilone, sagopilone,RNAi
screening, spindle assembly checkpoint, mitotic kinesins
INTRODUCTION
Breast cancer is the most prevalent cancer worldwide, with 2002
global statistics reporting >1 million new cases diagnosed annu-
ally and >400,000 deaths (Parkin et al., 2005). The treatment of
breast cancer is complicated by the diversity of breast tumor types
resulting from variation in their associated transcriptional pro-
grams (Perou et al., 2000). Molecular characterization of breast
cancer has led to the determination of a number of different
subtypes and gene expression signatures that correlate with clin-
ical factors such as prognosis, tumor recurrence, and survival
(Sørlie et al., 2001; Wang et al., 2005). As a consequence, there
has been a shift toward more tailored therapies against spe-
ciﬁc disease types in the clinic (Hatake et al., 2007), for exam-
ple, the addition of trastuzumab/lapatinib to chemotherapy for
HER2-positive tumors. This combination approach is changing
the standards of care in breast cancer (National Comprehensive
Cancer Network, 2008). Optimal treatment for patients suffer-
ing from this heterogeneous disease will increasingly rely on gene
expression/biomarker analysis to determine the most appropri-
ate patient population for each treatment and the best therapy
combinations for each patient, balancing response, and tolera-
bility while avoiding resistance. This remains a major challenge
(Gonzalez-Angulo et al., 2007) and it is therefore important to
combine the development of new therapeutic agents for patients
with breast cancer with research into optimal patient populations
and tailored treatment combinations at the earliest opportunity.
Microtubule-stabilizing taxanes (for review see Jordan et al.,
1993; Wahl et al., 1996; Jordan and Wilson, 2004; Risinger et al.,
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2009) are major contributors to successful breast cancer treatment
regimens when given as combination therapy. However, resistance
may develop because of mechanisms that include PgP efﬂux trans-
porter systems (Horwitz et al., 1993). Sagopilone, the ﬁrst fully
synthetic epothilone in clinical development, was optimized to
overcome the limitations associated with conventional tubulin-
binding agents, by combining high potency with a balanced safety
proﬁle (Klar et al., 2006). It has demonstrated high in vitro and
in vivo activity against a range of tumor models compared with
paclitaxel and other commonly used chemotherapy agents (Klar
et al., 2006) and, given its speciﬁc and superior tubulin targeting
activity (Hoffmann et al., 2008), sagopilone may have a potential
in the treatment of breast cancer.
Sagopilone activity and its molecular mode of action have
already been studied thoroughly in several other types of cancer.
Similar to other microtubule-stabilizing agents, sagopilone inter-
feres with microtubule dynamics with low concentrations leading
to abnormalmitosis andhigher concentrations resulting inmitotic
arrest (Torres and Horwitz, 1998; Chen et al., 2003; Winsel et al.,
2011). Following mitotic arrest, apoptosis is induced via loss of
mitochondrial membrane potential resulting in the activation of
the apical caspases 3 and 9 in HCT116 colon cancer cells (Hoff-
mann et al., 2008). Here, we present data describing sagopilone’s
mechanisms of proliferation inhibition in breast cancer cells.
To deepen our understanding of the molecular mode of action
and possible resistance mechanisms we identiﬁed genes whose
activity putatively modify sagopilone activity. Our knowledge-
based selection contained genes previously seen to be regulated by
sagopilone or paclitaxel (Hammer et al., 2010; Winsel et al., 2011),
genes previously described as predictors for paclitaxel and/or doc-
etaxel sensitivity (Bergstralh and Ting, 2006; Potti et al., 2006;
Swanton et al., 2007), genes reported in chromosomal instability
(CIN) signatures (Kim et al., 2004), and genes with the follow-
ing gene ontology annotations: drug transport, drug metabolism,
tubulin, spindle assembly checkpoint (SAC), cell cycle control, or
microtubule-associated proteins (http://www.ebi.ac.uk/GOA).We
employed the RNAi screening technology (Swanton et al., 2007;
Whitehurst et al., 2007) to determine the modifying effects of
reduced gene expression on sagopilone activity in breast cancer
cell lines.
Breast cellsmay be driven intomalignant proliferation bymany
different pathways, such as over-expressed/constitutively active
growth or transcription factors, apoptotic or survival pathway
defects or abnormalities in SAC control (Carvalho et al., 2003;
Sudo et al., 2004; Huang et al., 2005; Groth-Pedersen et al., 2007).
The aim of the studies presented in this paper, was to examine the
activity of sagopilone in vitro in a broad range of breast tumor
models. An RNAi drug modiﬁer screen was employed to investi-
gate possible resistance mechanisms and predictors of response,
and potentially provide a rationale for combining sagopilone with
other therapies to eventually deliver tailored treatment.
RESULTS
IN VITRO PROFILE OF SAGOPILONE IN BREAST CANCER CELL LINES
The growth inhibitory effect of sagopilone was compared with
ixabepilone and paclitaxel in 20 breast cancer cell lines in a
proliferation assay (Figure 1A). Sagopilone inhibited prolifera-
tion more strongly than ixabepilone or paclitaxel in all breast
tumor cell lines tested,with IC50 values ranging from0.2 to 1.8 nM.
Moreover, sagopilone was effective at sub-nanomolar concentra-
tions (≤1 nM) in the majority of these cell lines (13 of 20). The
activity of sagopilone was examined in both estrogen receptor α
(ERα)-positive and ERα-negative breast cancer cell lines. Sagopi-
lone strongly inhibited the growth of six ERα-positive (mean IC50
1.2± 0.9 nM) and the ERα-negative (mean IC50 0.9± 0.4 nM)
breast cancer cell lines (Figure 1A). Previously, the uptake of
sagopilone in A549 lung cancer cells was shown to be more rapid
and effective than that of paclitaxel (Hoffmann et al., 2008). The
anti-proliferative activity of sagopilone, ixabepilone, andpaclitaxel
were compared after different drug incubation times (Figure 1B).
The IC50 values indicate that sagopilone elicits a stronger and
more rapid anti-proliferative effect than paclitaxel after 1–72 h
drug incubation. In addition, the minimal IC50 was reached for
sagopilone after only 1 h incubation, while it took at least 7 h
of drug incubation for ixabepilone and paclitaxel to reach their
respective minimal IC50.
SAGOPILONE INTERFERES WITH CYTOSKELETAL FUNCTIONS AND
AFFECTS CELL CYCLE IN BREAST CANCER CELL LINES
Vehicle-treatedMDA-MB-231 breast cancer cells showed a normal
microtubule spread in interphase cells and typical bipolar spindle
with congressed chromosomes at the metaphase plate in mitotic
cells (Figure 2). Treatment with 3 nM sagopilone-induced mul-
tipolar spindles in mitotic cells while interphase cells were not
affected. In contrast, MDA-MB-231 breast cancer cells incubated
with 40 nM sagopilone exhibited marked microtubule bundling
in interphase cells, which led to an abnormal spindle organi-
zation in metaphase cells, with multiple spindle poles, several
plates of congressed chromosomes, and an irregular chromosomal
alignment.
Sagopilone-induced cell cycle arrest was quantiﬁed in MDA-
MB-231, T47D, MCF7, SKBR3, and MDA-MB-435s breast cancer
cells (Figure 3) using ﬂuorescence-activated cell sorter (FACS)
analysis (see Materials and Methods for discussion of origin of
MDA-MB-435s cells). Two different phenotypes were observed.
Low concentrations of sagopilone (<5 nM) induced aberrant cell
division resulting in the formation of increasing numbers of ane-
uploid cells with reduced DNA content, but mitotic arrest was not
induced. A second phenotype was observed at higher concentra-
tions of sagopilone (≥10 nM),where the cell cycle progression was
blocked in G2/M phase reaching a maximum after 18 h of incu-
bation. The sagopilone concentration required to induce mitotic
arrest varied between cell lines, but the maximal percentages
of cells in mitotic arrest reached 70–80% for all ﬁve cell lines.
Independently of the phenotype at high or low sagopilone con-
centrations, treatment with sagopilone resulted in the inhibition
of cell proliferation.
SAGOPILONE LEADS TO APOPTOSIS AND SENESCENCE
The activity of caspase 3 and 7 was compared in ERα-negative
(MDA-MB-231, MDA-MB-435s, SKBR3) and the ERα-positive
(MCF7, T47D) breast cancer cells after 48 h incubation with
sagopilone (Figure 4A). Caspase 3/7 activity was detected at
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FIGURE 1 | Sagopilone inhibits proliferation in breast cancer cell lines
irrespective of ERα status. (A) Inhibition of proliferation in 20 breast cancer
cell lines by sagopilone, ixabepilone, and paclitaxel after 72 h. Cell lines were
sorted according to their estrogen receptor α (ERα) status. Mean IC50 values
and SDs of triplicate experiments are shown. (B) Anti-proliferative effects of
sagopilone, ixabepilone, and paclitaxel on MCF7 cells after incubation times
ranging from 1 to 72 h. Mean IC50 values and SDs of triplicate experiments are
shown.
FIGURE 2 | Effect of sagopilone on tubulin cytoskeleton in
MDA-MB-231 breast cancer cells. Immunoﬂuorescence staining of
α-tubulin (green) and DNA (red) in MDA-MB-231 breast cancer cells after
incubation for 20 h with either vehicle (ethanol), 3 or 40 nM sagopilone
(Sag). Scale bar=20μm. Images representative of more than ﬁve
independent experiments.
low and high concentrations of sagopilone in all cell lines but
not in the caspase 3-negative MCF7 cell line. After 72 h incu-
bation, a concentration-dependent loss of cellular vitality was
observed in MDA-MB-231, SKBR3, MCF7, and T47D breast can-
cer cells (Figure 4B). Among the remaining vital cells, loss of
mitochondrial membrane potential was detected at low and high
concentrations of sagopilone.
In order to analyze the colony forming potential of cells remain-
ing vital in the presence of sagopilone, clonogenic assays were
performed (Figure 5A). A 2-h incubation with 100 nM sagopi-
lone completely inhibited colony forming in T47D, SKBR3, and
A549 cancer cells, but only partially in MCF7 cancer cells. A 24-h
treatment with 0.1 nM sagopilone reduced colony formation sig-
niﬁcantly in all four cell lines tested. However,MCF7 breast cancer
cells were the most resistant, forming even after 24 h treatment
with 100 nM sagopilone still∼20% of the colonies in comparison
to the vehicle-treated cells.
Though low-dose treatment (sagopilone concentration
approximately equivalent to IC50, below 3 nM) reduced colony
formation, cells remained vital for weeks (microscopic obser-
vation, images not shown). As induction of senescence might
be one additional mechanism for the growth inhibitory effect
of sagopilone at low concentrations – we investigated induction
of senescence-associated β-galactosidase (Dimri et al., 1995) in
sagopilone-treated cells. Cellular senescencewas twofold increased
in T47D cells at 1 nM sagopilone (Figure 5B).
RNAi DRUG MODIFIER SCREEN REVEALS SPINDLE ASSEMBLY
CHECKPOINT PROTEINS AND MITOTIC KINESINS AS MODIFIERS OF
SAGOPILONE ACTIVITY
Regardless of breast cancer heterogeneity, sagopilone consistently
inhibited tumor cell proliferation in vitro. In order to investigate
the mechanisms behind the activity of sagopilone, the knock-
down of 300 genes implicated in cell cycle control, apoptosis,
CIN, and taxane resistance was combined with sagopilone treat-
ment in a high-throughput RNAi drug modiﬁer screen in three
breast cancer cell lines MCF7, T47D, and MDA-MB-435s and,
for comparison, the A549 lung cancer cell line (see Materials and
Methods for discussion of MDA-MB-435s origin). The screen
was based on microscopic evaluation of DNA-stained nuclei. Pre-
liminary experiments showed that after 24 h of sagopilone treat-
ment the percentage of nuclei with condensed chromatin reﬂects
sagopilone-induced mitotic arrest. In order to evaluate both sensi-
tizing and suppressing effects of RNAi-mediated knockdown, two
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FIGURE 3 | Effect of sagopilone on cell cycle distribution of
breast cancer cells. (A) Cell cycle distribution of MDA-MB-231
cells treated with vehicle (ethanol), 3, 10, or 40 nM sagopilone (Sag)
for 20 h. (B) Percentages of cells with subG1 DNA content (left) and
cells in G2–M phase (right) for breast cancer cell lines MDA-MB-231,
T47D, MCF7, SKBR3, and MDA-MB-435s treated with vehicle (ethanol) or the
indicated concentrations sagopilone for 18 h (20 h for MDA-MB-231). Means
and SDs of triplicate experiments are shown for MCF7, MDA-MB-231, and
SKBR3 cells. Result of one experiment shown for T47D and
MDA-MB-435s cells.
sagopilone concentration levels were chosen so that the higher
level but not the lower led to mitotic arrest. The screening data are
available in the Supplementary Material.
The strongest suppressor effects were observed for the knock-
down of components of the SAC (Figure 6A). The knockdown
of components of the chromosomal passenger complex INCENP
and CDCA8 (Borealin), of the spindle protein CKAP5 (CHTOG)
and the mitotic checkpoint kinases BUB1B and MAD2L1 reduced
sagopilone-induced mitotic arrest signiﬁcantly in all four cell
lines with at least two of three siRNAs. Knockdown of BUB1
and TTK (MPS1) components of the mitotic checkpoint com-
plex, reduced mitotic arrest signiﬁcantly in MCF7 and A549 cells
but had little or no effect on T47D and MDA-MB-435s cells.
The protein CENPE functions both as mitotic kinesin (KIF10)
and as signaling component of the SAC. Its knockdown sup-
pressed sagopilone effects in MCF7 and MDA-MB-435s cells. The
knockdown of tubulin K-ALPHA1 and kinesin KIF2C (MCAK)
resulted in the strongest sensitizing effects in three or four cell
lines, respectively (Figure 6B). Other sensitizing gene knockdowns
affected only two of four cell lines. A pronounced effect displayed
the knockdown of kinesin KIF11 (EG5), which potentiated the
sagopilone-induced mitotic arrest in MCF7 and A549 cell lines.
None of the genes involved in drug transport and metabolism,
apoptosis, cell cycle control other than mitosis, or other functional
classes screened showed signiﬁcant modiﬁer effects in the chosen
screening set-up.
THE KNOCKDOWN OF THE SAC COMPONENTS BUB1B AND CENPE
REDUCES SAGOPILONE ACTIVITY
To validate modiﬁer effects observed for the knockdown of SAC
components, the kinases BUB1B and CENPE were chosen. Vali-
dation experiments were performed in ERα-positive MCF7 and
T47D breast cancer, in ERα-negative SKBR3 breast cancer (substi-
tuting MDA-MB-435s cell line, see Materials and Methods for dis-
cussion) and A549 lung cancer cell lines. The experiments aimed
to examine the knockdown effect on sagopilone-induced subG1
aneuploidy, sagopilone-induced mitotic arrest, and the inhibition
of proliferation by sagopilone (Figure 7A).
siRNA-mediated mRNA knockdown was achieved for both
genes with three siRNAs in all four cell lines (Figure 7B). The
mRNA knockdown remained stable after 24 h sagopilone treat-
ment (data not shown). Successful protein knockdown was shown
in MCF7 cells (Figure 7C). It was also conﬁrmed that nei-
ther BUB1B nor CENPE knockdown on its own inﬂuenced the
parameters to be measured (Figures 8 and 9).
To address the inﬂuence of BUB1B and CENPE knockdown on
the low-dose phenotype of sagopilone, theDNAcontent of siRNA-
transfected cells treated for 24 h with vehicle or low-dose sagopi-
lone (1 nM) was analyzed (Figure 8). Neither BUB1B nor CENPE
knockdown affected sagopilone-induced subG1 aneuploidy in any
of the four cell lines.
Next, the inﬂuence of BUB1B and CENPE knockdown on
sagopilone-induced mitotic arrest was studied by FACS analysis
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FIGURE 4 | Sagopilone induces caspase activity, loss of mitochondrial
membrane potential and loss of vitality in MCF7,T47D, SKBR3, and
MDA-MB-231 breast cancer cells. (A) Chemiluminescence-based
measurement of caspase 3/7 activity in cell lysates after 48 h of treatment
with either vehicle (ethanol) or sagopilone. RLU, relative light units. Means
and SDs of triplicate experiments are shown. (B)The percentages of dead
cells (PI+, black) and vital cells characterized by loss of mitochondrial
membrane potential (PI−, ΔΨm low, white) were determined following
treatment with vehicle (ethanol) or indicated concentrations of sagopilone for
72 h. Mean percentages and SDs given (n =2).
FIGURE 5 | Sagopilone reduces colony formation and induces
senescence. (A) Clonogenic assays in MCF7, T47D, SKBR3 breast
cancer and A549 lung cancer cells. Sagopilone was added 24h after
seeding for either 2 h (left) or 24 h (right). Afterward, cells were cultured
without sagopilone for additional 10–14 days. Colonies were ﬁxed with
glutaraldehyde, stained with crystal violet, and counted. The number of
colonies obtained under sagopilone treatment was normalized to the number
of colonies in vehicle-treated samples. Means and SDs of triplicate
experiments are given. (B) Senescence assay in T47D breast cancer cells.
Sagopilone (Sag), doxorubicin (Dox, positive control), or vehicle (ethanol) were
added 24 h after seeding of cells for 6 days. Cells were ﬁxed and treated with
X-gal for staining of β-galactosidase. The percentage of
β-galactosidase-positive cells was calculated. Means and SDs of triplicate
measurements are given.
of the DNA content of cells treated for 24 h with vehicle or
sagopilone (1, 40 nM; Figure 9). The knockdown of both genes
reduced the sagopilone-induced mitotic arrest in MCF7, T47D,
and SKBR3 cells. This effect was not visible in A549 cells, likely
due to saturation of the mitotic arrest at the applied sagopilone
concentration. Using microscopic evaluation of phospho-histone
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FIGURE 6 |Top candidate modifiers in RNAi sagopilone modifier screen.
The modiﬁer effect of RNAi-mediated knockdown on sagopilone-induced
mitotic arrest was analyzed for over 300 genes in MCF7, T47D, A549, and
MDA-MB-435s cell lines with three different siRNAs per gene. Controls and
transfected cells were treated with vehicle, low-dose, and high-dose
sagopilone. Screening conditions, data analysis, and ranking of modiﬁer
effects are detailed in Section “Materials and Methods.”
Index>1=enhancement of sagopilone effects, index<1= suppression of
sagopilone effects. (A) Strongest suppressor effects (index calculated for
high-dose treatment). (B) Strongest sensitizer effects (index calculated for
low-dose treatment). Both panels ranked according to strength of modiﬁer
effect.
positive nuclei, the reduction of sagopilone-induced mitotic arrest
was also demonstrated in A549 cells (data not shown).
Crystal violet-based proliferation assays were chosen to assess
the modiﬁer effect on proliferation inhibition (Figure 10). Two
parameters were analyzed: IC50 values and survival indices indica-
tive of cells surviving 72 h treatment with 100 nM sagopilone. It
was demonstrated that neither BUB1B nor CENPE knockdown
affected IC50 values in any of the four cell lines. In contrast, sur-
vival indices were increased for BUB1B knockdown in all four cell
lines and for CENPE knockdown in T47D cells.
THE KNOCKDOWN OF THE KINESINS KIF11 AND KIF2C ENHANCES
SAGOPILONE ACTIVITY
In order to validate the modiﬁer effects observed for the knock-
down of the mitotic kinesins KIF11 and KIF2C, similar experi-
ments as described above for the SACcomponentswere performed
in parallel.
siRNA-mediated mRNA knockdown was achieved for KIF2C
using three different siRNAs in all four cell lines (Figure 7B) and
remained stable under sagopilone treatment (data not shown).
The KIF2C knockdown was also shown on protein level in MCF7
cells (Figure 7C) and did not affect the parameters under ques-
tion (Figures 8 and 9). Low sagopilone concentrations (1 nM)
induced the typical low-dose phenotype of subG1 aneuploidy
(Figure 8). The simultaneous knockdown of KIF2C reduced sig-
niﬁcantly the number of cells with subG1DNA content. Also, it led
to a signiﬁcant increase in the amount of G2/M cells at low sagopi-
lone concentration (1 nM; Figure 9). Thus, KIF2C knockdown
enhanced sagopilone-induced mitotic arrest. IC50 values and sur-
vival indices of proliferation inhibition remainedunchangedwhen
KIF2C expression was reduced in all four cell lines (Figure 10).
For KIF11, the mRNA knockdown was only limited for three
different siRNAs (Figure 7B). A fourth siRNA, directed against
all four KIF11 isotypes, displayed a strong knockdown but also a
phenotype with pronounced mitotic arrest and increased lethal-
ity. Gene knockdown was also shown on protein level in MCF7
cells (Figure 7C). At 1 nM sagopilone, a signiﬁcant reduction of
sagopilone-induced aneuploidy was seen for KIF11 knockdown
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FIGURE 7 | RNAi-mediated knockdown of BUB1B, CENPE,
KIF2C, and KIF11 in MCF7,T47D, SKBR3, and A549 cancer cell
lines. (A) Experimental set-up. (B) mRNA level measured by
qRT-PCR in samples 24 h after RNAi transfection. Reference gene:
HPRT. Normalization to gene level in untransfected control. Means
and SDs for three independent transfection experiments. (C)Western
Blot of MCF7 cell lysates prepared 48 h after RNAi transfection.
Samples: u, untransfected, m, mock transfection, n, negative control
siRNA, 1/2/3, gene-speciﬁc siRNAs for BUB1B, CENPE, and KIF2C (for
KIF11: 1/2/3/4).
in all cell lines for all siRNAs achieving a signiﬁcant knock-
down (Figure 8). Also, the IC50 values of proliferation inhibi-
tion increased relative to controls (mock transfected, negative
non-targeting siRNA transfected) after successful KIF11 knock-
down but survival indices of proliferation inhibition remained
unchanged (Figure 10).
To further elucidate the inﬂuence of KIF11 on the induc-
tion of aneuploid cells after low-dose sagopilone treatment, we
compared the RNAi-mediated knockdown of KIF11 with the
effect of ispinesib treatment, a small molecule inhibitor of KIF11
(Purcell et al., 2010). Similar to the RNAi-mediated knockdown
of KIF11, ispinesib signiﬁcantly reduced the sagopilone-induced
aneuploidy without increasing mitotic arrest (Figure 11A). The
combination of sagopilone and ispinesib had antagonistic effects
in proliferation assays of T47D, MCF7, SKBR3, and MDA-
MB-231 breast cancer cell lines (Figure 11B). Both KIF11
knockdown and KIF11 inhibition caused typical monoasters
(Figures 11C,D). Thus, interference with spindle assembly by
KIF11 inhibition speciﬁcally antagonizes the low-dose sagopilone-
induced aneuploidy but not the sagopilone-induced mitotic
arrest.
To conclude, silencing of ﬁve out of the 300 RNAi-targeted
genes had an antagonistic effect on sagopilone in all four cell
lines in the screen (MAD2L1, INCENP,CDCA8,CKAP5, BUB1B);
silencing of another four genes had an antagonistic effect in at least
two cell models (BUB1, TTK, CENPE, KNTC2). On the other
hand, silencing of one out of the 300 genes had a sensitizing effect
on sagopilone in all four cell lines (KIF2C); silencing of another
ﬁve genes had a sensitizing effect in at least two cellmodels (KIF2C,
K-ALPHA1,CHAF1A,MAP7,KIF11). From these candidatemod-
iﬁer target genes, validation studies have so far conﬁrmed modiﬁer
effects for four genes (BUB1B, CENPE, KIF11, and KIF2C).
DISCUSSION
The general cellular and molecular mechanisms of sagopilone,
a new epothilone, have been described earlier (Hoffmann et al.,
2008). Here we report additional data, conﬁrming that sagopi-
lone produces also rapid cellular effects in breast cancer cell lines,
including both ERα-positive and ERα-negative tumors, resulting
in considerable anti-proliferative activity, even after short incuba-
tion times, due to its fast uptake and high afﬁnity and selectivity
to its target β-tubulin (TUBB1).
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FIGURE 8 | RNAi-mediated knockdown of KIF11 and KIF2C
reduces sagopilone-induced aneuploidy. MCF7, T47D, SKBR3,
and A549 cancer cells were transfected with siRNAs speciﬁc for
BUB1B, CENPE, KIF11, or KIF2C. Vehicle or 1 nM sagopilone were
added 24 h post transfection. Cells with subG1 DNA content were
quantiﬁed by FACS analysis of PI-stained cells 24 h post drug addition.
Samples: u, untransfected, m, mock transfection, n, negative control siRNA,
1/2/3, gene-speciﬁc siRNAs for BUB1B, CENPE, and KIF2C, for KIF11:
1/2/3/4. Mean percentages and SDs of three transfection experiments are
given. ∗Marks if P <0.05 (t -test, two-sided) for comparison of
difference= (drug-treated–untreated) between transfected sample and
control (negative siRNA).
FIGURE 9 | RNAi-mediated knockdown of BUB1B and CENPE reduces
sagopilone-induced mitotic arrest while RNAi-mediated knockdown of
KIF2C enhances sagopilone-induced mitotic arrest. MCF7, T47D, SKBR3,
and A549 cancer cells were transfected with siRNAs speciﬁc for BUB1B,
CENPE, KIF11, or KIF2C. Vehicle, 1 or 40 nM sagopilone were added 24 h post
transfection. Cells with G2–M-DNA content were quantiﬁed by FACS analysis
of PI-stained cells 24 h post drug addition. Samples: u, untransfected, m,
mock transfection, n, negative control siRNA, 1/2/3, gene-speciﬁc siRNAs for
BUB1B, CENPE, and KIF2C, for KIF11: 1/2/3/4. Mean percentages and SDs of
three transfection experiments are given. ∗ Marks if P <0.05 (t -test,
two-sided) for comparison of difference= (drug-treated–untreated) between
transfected sample and control (negative siRNA).
As seen in other tumor cell lines, the anti-proliferative activity
of sagopilone is more potent than that of paclitaxel or ixabepi-
lone across breast cancer cell lines. A retrospective analysis of
patient-derived breast cancer tissue has indicated that estrogen
receptor α (ERα) positive tumors were more resistant to six anti-
cancer agents than ERα-negative tumors and ixabepilone response
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FIGURE 10 | RNAi-mediated knockdown of BUB1B enhances
survival of sagopilone-treated cells. MCF7, T47D, SKBR3, and
A549 cancer cells were transfected with siRNAs speciﬁc for
BUB1B, CENPE, KIF11, or KIF2C. Vehicle or sagopilone were
added 24 h post transfection. IC50 and survival index were
calculated for 72 h proliferation assays. Samples: u, untransfected, m, mock
transfection, n, negative control siRNA, 1/2/3, gene-speciﬁc siRNAs for
BUB1B, CENPE, and KIF2C, for KIF11: 1/2/3/4. No data available for KIF11 #4
due to high lethality. Means and SDs of three transfection experiments
are given.
FIGURE 11 | Antagonistic combination of sagopilone and
ispinesib. (A) Quantiﬁcation of subG1 and G2/M cells by FACS
analysis of PI-stained MDA-MB-231 breast cancer cells. Means and
SDs from triplicate experiments. ∗∗ Marks P <0.001 (t -test,
two-sided) for comparison subG1 percentage induced by 1 nM
sagopilone with vs. without ispinesib. (B) Combination of sagopilone and
ispinesib in proliferation assay of MCF7, T47D, SKBR2, and MDA-MB-231
breast cancer cells. Calculation of combination index (CI) according to Chou
(2006). Means and SDs for CI from three independent experiments. (C)
Induction of monoasters by KIF11 knockdown in MDA-MB-231 cells.
Immunoﬂuorescence staining with Hoechst33342 (DNA) and α-Tubulin–FITC.
Scale bar=10μm. (D) Quantiﬁcation of monoaster induction by KIF11
knockdown or KIF11 inhibition with ispinesib. Manual count, means, and SDs
from triplicate experiments.
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has been associated with low levels of ERα expression (Maehara
et al., 1990; Pusztai, 2007). In our study, we show that sagopi-
lone potently inhibited tumor cell proliferation in all ERα-positive
cell lines. Comparable anti-proliferative effects were observedwith
sagopilone treatment of ERα-negative tumor cells, suggesting that
sagopilone may represent a therapeutic option for ERα-positive
tumors, especially in an adjuvant setting or if tumors have become
hormone independent.
In the past microtubule-targeting drugs were generally believed
to cause mitotic arrest, but more detailed studies have identiﬁed
two concentration-dependent phenotypes (Torres and Horwitz,
1998; Chen et al., 2003; Winsel et al., 2011). We were able to show
that this is also the mode of action of sagopilone in breast cancer
cells. At low concentrations (<5 nM), sagopilone affects spindle
morphology without causing mitotic arrest. Low sagopilone con-
centrations lead to the formation of multipolar, yet functional
spindles. Multipolar mitosis produces vital cells with reduced,
aneuploid DNA content. We demonstrated that siRNA knock-
down of SAC components does not affect the sagopilone-induced
aneuploidy. The concentration range inducing subG1 aneuploidy
also inhibited cell proliferation indicating that subG1 aneuploidy
induction may be one mechanism responsible for proliferation
inhibition. This is supported by our data on KIF11 inhibition
which reduces sagopilone-induced aneuploidy and also antago-
nizes proliferation inhibition. In part responsible for the inhibition
of proliferation may be apoptosis and senescence. We show loss of
mitochondrial membrane potential and caspase activation which
have been described as hallmarks of sagopilone-induced apoptosis
in HCT116 colon cancer cells (Hoffmann et al., 2008). Previously,
we have shown inA549 lung cancer cells that the activationof TP53
by low sagopilone concentrations protects cells from apoptosis
and leads to G1-like arrest (Winsel et al., 2011). Prolonged G1-like
arrest may ultimately lead to senescence as we have shown here.
Recently, Weaver and Cleveland (2007) demonstrated that gross
aneuploidy leads to tumor suppression. The mechanism of prolif-
eration inhibition by sagopilone-induced subG1 aneuploidy was
observed in the breast cancer cell lines MCF7, T47D, MDA-MB-
231, SKBR3, and MDA-MB-435s independently of ERα-status.
However, MCF7 cells were to some degree resistant, retaining cer-
tain colony forming capacity even after sagopilone treatment. Of
the ﬁve cell lines, MCF7 cells display the highest degree of poly-
ploidy, being near tetraploid. Possibly, the risk of cells escaping
the G1-arrest or overcoming the drawbacks of gross aneuploidy
increases with polyploidy. In addition,MCF7 cells lack the activity
of the apical caspase 3 so that apoptosis induction may not be as
efﬁcient.
A different phenotype appears to be induced at higher sagopi-
lone concentrations, with progressively more perturbed micro-
tubule dynamics, formation of microtubule bundles and activa-
tion of the SAC leading to an arrest inmitosis. Sagopilone-induced
mitotic arrest was demonstrated in the breast cancer cell lines
MCF7, T47D, MDA-MB-231, SKBR3, and MDA-MB-435s inde-
pendently of ERα-status. Followingmitotic arrest,we observed the
induction of caspase 3/7 activity (not in caspase 3-deﬁcient MCF7
cells) and loss of mitochondrial membrane potential. This indi-
cates induction of mitochondrial apoptosis substantially similar to
that seen with paclitaxel and other epothilones (Hoffmann et al.,
2008). Recently, it was demonstrated that the extent of apoptosis
followingmitotic arrestmay vary according to differences in apop-
totic signaling (Shi et al., 2008).Other exits fromprolongedmitotic
arrest include aberrant mitosis,mitotic slippage, and endoredupli-
cation.Near tetraploidy, prove of previous aberrantmitotic events,
and weakened apoptotic efﬁciency due to caspase 3 deﬁciency may
explain the low, yet persistent colony forming ability of MCF7 cells
even after 24 h treatment with 100 nM sagopilone. Nonetheless, so
far we did not succeed in raising any sagopilone-resistant clone
in vitro.
Furthermore, results of the RNAi drug modiﬁer screen under-
lined that the function of the SAC determines sagopilone activity.
Of the 300 genes that were screened, mainly candidate genes
involved in SAC exhibited modiﬁer effects in all four cell lines.
Neither drug transport, metabolic genes nor other previously
described mechanisms of paclitaxel resistances inﬂuenced sagopi-
lone action. Within the short observation time and the chosen
screening set-up, the previously published importance of pro-
apoptotic genes for sagopilone-induced apoptosis (Hoffmann
et al., 2008) was not seen.
Mitotic spindle formation is fundamental to mitosis and there-
fore it would be expected that components of this process have
an impact on the antitumor activity of microtubule-targeting
drugs. The SAC postpones anaphase until all kinetochores are
attached to both spindle poles (Zhou et al., 2002; Musacchio
and Salmon, 2007). If the SAC is weakened by mutation or gene
knockdown, cells can continue with mitosis without complete
kinetochore attachment or exit aberrantly frommitosis after arrest
without subsequent apoptosis (Tao et al., 2005). This has been
conﬁrmed in experiments where important SAC components, i.e.,
BUB1B and CENPE, have been knocked down and suppression
of sagopilone-induced mitotic arrest and increased cell survival
was observed in several breast cancer cell lines. The dysfunction of
SAC components has previously been shown to generate paclitaxel
resistance (Carvalho et al., 2003; Sudo et al., 2004; Swanton et al.,
2007;Weaver andCleveland,2007). Interestingly, clinical paclitaxel
resistance in colorectal cancer has been linked to CIN, which is
associated with the abnormal expression of certain SAC regulators
(Swanton et al., 2006; Harrison and Swanton, 2008). Incidentally,
mutations in CIN genes have been linked to increased mortality
in breast cancer patients (Brendle et al., 2008). The inﬂuence of
CIN on sagopilone activity in the clinic, however, remains to be
determined.
Mitotic kinesins are required for spindle formation and chro-
mosome alignment and thus central to fulﬁlling SAC demands.
In phase I of mitosis, centrosomes are separated by the KIF11
(EG5) motor function (Zhu et al., 2005). Inhibition of KIF11
by RNAi-mediated knockdown or synthetic inhibitor reduced
sagopilone-induced spindle multipolarity and subsequent aneu-
ploidy. On the other hand, sagopilone countered the monopo-
larity caused by KIF11 inhibition. Our data suggest, that sagopi-
lone induces ectopic spindle poles as described for epothilone B
(Sakaushi et al., 2008). These ectopic spindle poles are indepen-
dent from microtubule-organizing centers. Due to their spatial
distribution, KIF11 activity is not required for the formation
of functional bipolar spindles. At the same time, KIF11 inhibi-
tion hinders the separation of the true spindle pole. Thus, as
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demonstrated here, the combined inﬂuence of KIF11 inhibition
and sagopilone re-establishes bipolar mitosis. In conclusion, the
reduction of sagopilone-induced aneuploidy, one of the mecha-
nisms of proliferation inhibition, is the molecular basis for the
antagonism measured here in proliferation assays for the combi-
nation of ispinesib and sagopilone. Recently, the combination of
docetaxel and ispinesib showed acceptable toxicity proﬁles with-
out pharmacokinetic drug interaction in a phase I trial (Blagden
et al., 2008). However, based on our molecular data, one would
not expect synergism between these drugs.
KIF2C (MCAK) plays a role in phase II of mitosis during
chromosome alignment and congression (Zhu et al., 2005). Its
knockdown reduced the sagopilone concentration required for
mitotic arrest. We hypothesize that the knockdown increases SAC
signaling thus synergizing with sagopilone. Recently, it has been
reported that cancer cells are more sensitive to KIF2C RNAi-
mediated knockdown than normal cells and that the knockdown
potentiates paclitaxel-inducedmitotic arrest (Hedrick et al., 2008).
Furthermore, KIF2C is upregulated in breast cancer (Shimo et al.,
2008). Thus, KIF2C inhibition seems to be a valuable combina-
tion strategy for sagopilone. The only KIF2C inhibitors known so
far, sulfoquinovosylacylglycerols, also inhibit DNA polymerases
(Aoki et al., 2005) and have therefore not been evaluated in
combination.
Summarizing the new experimental data, sagopilone shows
superior activity across a range of heterogeneous breast cancer
models compared with other anticancer agents, including estab-
lished (paclitaxel) and recently approved (ixabepilone) breast
cancer treatments. In all breast cancer models studied here, the
same sagopilone phenotypes were observed. Proliferation inhibi-
tion due to aneuploid cell divisions at low-dose was superseded
by mitotic arrest and apoptosis at higher doses. Key modulator of
sagopilone activity was the SAC. Drug combination synergism is
likely to result from combined activation of the SAC. Therefore,
the SAC activity status (i.e., expression levels, polymorphisms,
mutations), especially of the central SAC kinase BUB1B, could
potentially deﬁne patient sub-populations for amore tailored drug
treatment.
MATERIALS AND METHODS
CELLS AND COMPOUNDS
Human cancer cell lines were obtained from the American Type
Culture Collection (ATCC), except for MX-1 (DKFZ, Heidel-
berg, Germany), EVSA-T (DSMZ, Braunschweig, Germany), and
SUM149 (Steven Ethier, University of Michigan Medical Cen-
ter, MI, USA). The cancer cell line MDA-MB-435s was also
obtained from the ATCC. MDA-MB-435s cancer cells were orig-
inally isolated from the pleural effusion of a 31-year-old female
with metastatic, ductal adenocarcinoma of the breast (Cailleau
et al., 1978). However, recent studies questioned the origin of the
parental cell line, MDA-MB-435. In gene expression microarray
analysis MDA-MB-435 clustered with cell lines of melanoma ori-
gin instead of breast cancer origin and MDA-MB-435 has been
reported to be cross-contaminated with the M14 melanoma line
(Chambers, 2009). Microsatellite analysis conﬁrmed that the cell
lines were identical (Hollestelle and Schutte, 2009). However,
Hollestelle et al. also showed that several basal type breast cancer
cell lines have a genetic basis similar to melanoma. Thus, they con-
clude that both MDA-MB-435 and M14 are breast cancer cell lines
of basal type (Hollestelle et al., 2009). The discussion of the MDA-
MB-435s origin was ongoing during the time of the performance
of the work presented here. For this reason,we substituted in some
experiments the MDA-MB-435s cell line with the SKBR3 cell line,
which is also ERα-negative.
Subconﬂuent tumor cells were cultured according to standard
protocols. For cells obtained from the ATCC or DKFZ, recom-
mended protocols were used. Cells obtained from the DSMZ were
passaged in RPMI 1640 medium and SUM149 cells were cultured
as previously described (Forozan et al., 1999).
Sagopilone (Klar et al., 2006), patupilone ixabepilone, and
ispinesib were synthesized at Bayer Healthcare Pharmaceuticals
(Berlin, Germany) through total syntheses. Paclitaxel and doxoru-
bicin were purchased from Sigma-Aldrich (Munich, Germany).
All substances were dissolved in ethanol, except for doxorubicin
which was dissolved in H2O. All media and supplements for cell
culture were purchased from Biochrom AG (Berlin, Germany).
Stock solutions were prepared as previously described (Lichtner
et al., 2001).
IN VITRO ANALYSIS OF SAGOPILONE ON TUMOR CELL PROLIFERATION,
CYTOSKELETON, CELL CYCLE, APOPTOSIS, AND SENESCENCE
The effect of sagopilone and other anticancer agents on the prolif-
eration of breast cancer cell lines was assessed using a cell prolifer-
ation assay based on crystal violet cell staining as described before
(Lichtner et al., 2001). IC50 values were calculated from three
independent experiments using the SigmaPlot software (SPSS,
Friedrichsdorf, Germany). The survival index was calculated as
ratio of cell number surviving a 72-h treatment with 100 nM
sagopilone divided by initial cell number (Shi et al., 2008). The
combined effect of sagopilone and ispinesib was measured in
cell proliferation assays. Here, the combination index (CI) was
calculated according to Chou (2006).
To visualize the effects of sagopilone on mitotic and inter-
phase microtubules, MDA-MB-231 cells were incubated with
vehicle (ethanol), 3 or 40 nM sagopilone for 20 h, ﬁxed with 4%
paraformaldehyde, and stained with a monoclonal mouse anti-
α-tubulin antibody (1:1000; Sigma-Aldrich, Munich, Germany),
Alexa Fluor® 488 goat anti-mouse IgG secondary antibody (1:250;
Invitrogen Inc., Carlsbad, CA, USA), and DRAQ5™(Biostatus,
Leicestershire, UK), according to standard protocols. Fixed and
stained cells were analyzed using a Zeiss LSM 510 META micro-
scope (Carl Zeiss AG, Jena, Germany) equipped with a Plan-
Apochromat® 63×/1.4 (oil DIC) objective. Zeiss LSM software
(version 3.0 SP3) was employed for confocal imaging. Alterna-
tively, cells were stained with mouse anti-α-Tubulin–FITC (1:200;
SIGMA-Aldrich) and Hoechst33342 (Invitrogen Inc., Carlsbad,
CA, USA). Images were taken on the OPERA automated micro-
scope (Evotec, Hamburg, Germany; 10× objective, binning_2)
and analyzed using MetaXpress Software (Molecular Devices,
Sunnyvale, CA, USA).
Fluorescence-activated cell sorter analysis was performed to
determine the distribution of cells in the cell cycle phases. Cells
were incubated with sagopilone for 20 h, ﬁxed with 70% ethanol,
and stained with 50μg/mL propidium iodide (PI; Sigma-Aldrich,
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Munich,Germany). CellularDNA contentwas determined by ﬂow
cytometry using the BD FACSCalibur™and statistically analyzed
using CellQuest™software (Becton, Dickinson and Company, San
Jose, CA, USA).
The activity of the apical caspases 3 and 7 was measured using a
commercial chemiluminescence-based caspase 3/7-Kit (Promega,
Madison, WI, USA). Cells were seeded at a density of 1000
cells/well in 96-well plates. At 24 h after cell seeding, sagopilone
or vehicle were added. After 48 h of treatment, cells were lysed,
and caspase 3/7 activity wasmeasured according tomanufacturer’s
instructions.
To investigate loss of mitochondrial membrane potential and
cellular vitality, breast cancer cells were incubated continuously for
72 h with vehicle or the indicated drug concentration of sagopi-
lone, trypsinized, stainedwith 3,3′-dihexyloxacarbocyanine iodide
(DiOC6(3); Invitrogen Inc., Carlsbad, CA, USA) and propidium
iodide as before (Castedo et al., 2002), measured by ﬂow cytom-
etry using the BD FACSCalibur™and statistically analyzed using
CellQuest™software (Becton, Dickinson and Company, San Jose,
CA, USA).
The amount of cellular senescencewas determined based on the
expression of senescence-associated β-galactosidase (Dimri et al.,
1995) using the Senescence Cells Histochemical Stain Kit (Sigma-
Aldrich, Munich, Germany). At 24 h after cell seeding, sagopilone
was added for 6 days. Doxorubicin was used as positive control
(Eom et al., 2005). Cells were ﬁxed and treated with X-gal for
staining of β-galactosidase according to manufacturer’s instruc-
tions. Stained and unstained cells were counted and the percentage
of β-galactosidase-positive cells was calculated.
RNA INTERFERENCE ANALYSES IN BREAST TUMOR MODELS
A non-redundant gene list was compiled from the following
sources: genes previously seen to be regulated by sagopilone or
paclitaxel (Hammer et al., 2010; Winsel et al., 2011), genes pre-
viously described as predictors for paclitaxel and/or docetaxel
sensitivity (Bergstralh and Ting, 2006; Potti et al., 2006; Swan-
ton et al., 2007), genes reported in CIN signatures (Kim et al.,
2004), and genes with the following gene ontology annotations:
drug transport, drug metabolism, tubulin, SAC, cell cycle control,
or microtubule-associated proteins (http://www.ebi.ac.uk/GOA).
The relative expression of 792 genes was analyzed in the three
breast cancer cell lines MCF7, T47D, and MDA-MB-435s and
the lung cancer cell line A549 in the in-house Array Northern
database based on results from by Affymetrix HGU133Plus2.0
arrays, and only genes with signiﬁcant expression in at least
two of the four cell lines were retained. These 300 genes were
targeted with three individual siRNAs per gene obtained from
Ambion (Austin, TX, USA, see Supplementary Material for
detailed information). The effects of gene knockdown in presence
and absence of sagopilone were then determined. The percent-
age of nuclei with condensed chromatin after 24 h of sagopilone
treatment was deﬁned as endpoint of the screen. In preliminary
experiments this has been established to reﬂect the mitotically
arrested cell population. For the screen, cells were seeded at
1.5× 103 (A549), 2× 103 (MCF7, MDA-MB-435s) or 4.5× 103
(T47D) cells/well in collagen I coated (except MDA-MB-435s)
384-well microplates (Greiner Bio-One GmbH, Frickenhausen,
Germany) and transfected after 24 h with 0.076μL Dharma-
FECT® 2 (Dharmacon, Inc., Lafayette, CO, USA) and 100 nM
siRNA in serum-containing medium. After 24 h, transfected cells
were incubated for 24 h with medium containing vehicle or
medium containing sagopilone at two different concentrations
each (8 and 20 nM for MCF7 and A549; 3 and 10 nM for
T47D and MDA-MB-435s), followed by paraformaldehyde ﬁxa-
tion and staining with Hoechst33342 (Invitrogen Inc., Carlsbad,
CA, USA). Imaging was performed on an MDC ImageXpress-
Micro™automated microscope (Molecular Devices, Sunnyvale,
CA, USA; 10× objective, binning_1, 4 sites/well), and Deﬁniens®
software (Deﬁniens AG, Munich, Germany) was used for image
analysis.
Each measurement was performed in triplicate. For each
treatment (vehicle, low level sagopilone, high level sagopilone),
the mean percentage per triplicate measurement of nuclei with
condensed chromatin was normalized to the sample median
of the treatment level. Normalized means and SDs of tripli-
cate measurement for each siRNA and each treatment level are
listed in the Supplementary Material. The modiﬁer effect of an
siRNA was graphically presented as index calculated by divid-
ing the normalized means of sagopilone-treated samples by the
normalized means of vehicle-treated samples. Thus, an index
greater than one indicates that the given siRNA enhanced sagopi-
lone activity, an index smaller than one that the given siRNA
reduced sagopilone activity. Modiﬁer effects were ranked accord-
ing to the following procedure: t -values were calculated for each
siRNA, comparing sagopilone-treated and vehicle-treated sam-
ples. All t -values belonging to a certain sagopilone concentration
and cell line were ranked in increasing order. Rank sums were
calculated for any combination of two out of the three siR-
NAs per gene. For candidate suppressors, the maximum rank
sums for high sagopilone concentrations were ranked in decreas-
ing order, for candidate sensitizers, the minimum rank sums
for low sagopilone concentrations were ranked in increasing
order.
The following siRNAs from Ambion (Austin, TX, USA)
were used for validation experiments: BUB1B (#88, #89, #90),
CENPE (#121337, #121338, #121339), KIF2C (#118444, #118445,
#118446), KIF11 (#118429, #118430, #118431, #s7902), negative
control siRNA (#D001210-03-20). 106 cells were electroporated
in the presence of 1μM siRNA using the Nucleofector I (AMAXA,
Cologne, Germany) according to manufacturer’s instructions.
Transfected cells were then plated at 1× 103 cells/well in 96-
well plates for proliferation assays, at 2× 104 cells/well in 6well-
plates (TPP, Trasadingen, Switzerland) for RNA extraction and
cell cycle analysis and at 5× 103 cells/well in μCLEAR black
96-well plates (Greiner Bio-One GmbH, Frickenhausen, Ger-
many) for immunoﬂuorescence staining. Sagopilone was added
24 h post transfection. RNA extraction and ﬁxation for both
cell cycle analysis and immunoﬂuorescence staining were done
24 h post sagopilone addition, while proliferation assay plates
were ﬁxed 72 h post sagopilone addition. RNA was extracted
using the RNeasy Mini Kit (Qiagen, Hilden, Germany) and
cDNA was generated using SuperScript First Strand Synthesis
System (Invitrogen Inc., Carlsbad, CA, USA). Real-Time qRT-
PCR was performed with gene expression assays from Applied
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Biosystems (Foster City, CA, USA): BUB1B (#Hs00176169_m1),
CENPE (#Hs00199232_m1), KIF2C (#Hs00156507_m1), KIF11
(Hs00189698_m1), and GAPDH (#4326317E). Reactions were
set-up in triplicates using the TaqMan FAST Universal PCR
Mastermix and recorded in a 7500 Fast Real-Time PCR-
System (Applied Biosystems, Foster City, CA, USA). For detec-
tion of protein knockdown the following primary antibodies
were used: mouse anti-human BUB1B #612502 (BD Trans-
duction Laboratories, San Jose, CA, USA), rabbit anti-human
CENPE #C7480 (Sigma-Aldrich, Munich, Germany), mouse anti-
human EG5 #627802 (BioLegend, San Diego, CA, USA), rabbit
anti-human MCAK #NB 100-2589 (Novus Biologicals, Littleton,
CO, USA).
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